Summary
The AI response asserts that the provided boxed-warning topic content is supported by the label’s Warnings & Precautions (sections 5.1–5.5), but the excerpts supplied by the user are not the exact AI response claims, and the AI response includes additional statements not fully verifiable from the provided excerpts (e.g., inability to confirm that the topics are specifically 'boxed warnings').
Category Scores
Accurate Statements
Label excerpts provided in the prompt include Warnings and Precautions content for serious infections (5.1), mortality (5.2), malignancy (5.3), MACE (5.4), and thrombosis (5.5), with related avoid/discontinue/interrupt language.
Supported by the user-supplied excerpts for sections 5.1–5.5 in the prompt (e.g., 5.1 avoid use in active serious infection; interrupt and do not resume until controlled; 5.4 discontinue after MI or stroke; 5.5 avoid increased thrombosis risk; discontinue and evaluate/treat if symptoms occur).
Ruxolitinib systemic concentrations may increase with strong CYP3A4 inhibitors and thus concomitant use should be avoided (drug interactions).
Supported by the user-supplied excerpt under Drug Interactions mentioning avoidance of strong CYP3A4 inhibitors.
Unsupported Statements
“The provided FDA-approved OPZELURA labeling explicitly includes boxed-warning topic content … and the corresponding detailed sections 5.1–5.5.”
The prompt includes section content excerpts (5.1–5.5) but does not provide the actual boxed-warning block or explicit confirmation that those specific topics are presented as boxed warnings in the label excerpt. The AI response asserts a boxed-warning characterization that is not directly verifiable from the provided material.
Contradictions
Important Omissions
A precise mapping statement tying each cited boxed-warning item to the exact boxed-warning text in the label (the boxed-warning block itself is not provided in the prompt excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response appears to correctly reference label sections that contain the described risk management instructions (avoid/interrupt/discontinue). However, the boxed-warning labeling characterization is not verifiably supported by the provided excerpts, reducing audit certainty.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The AI response claims the content is explicitly 'boxed-warning topic content' and that boxed warnings correspond to 5.1–5.5, but the boxed-warning block itself is not provided in the prompt excerpts, so this boxed-warning characterization cannot be confirmed.
Suggested Improvement
Quote or reference the actual boxed-warning text block from the label excerpt, then map each boxed-warning item to the specific Warnings/Precautions paragraphs (5.1–5.5) using exact wording and citations.